Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 52

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 52
---
 not declared or paid regular cash dividends on its common stock. The terms of the Merger Agreement limit Enfusion’s ability to declare or pay dividends prior to the completion of the Merger. 28

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Proxy Statement/Prospectus and the documents incorporated by reference into this Proxy Statement/Prospectus contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that are not limited to historical facts but reflect Clearwater’s and Enfusion’s current beliefs, expectations or intentions regarding future events. These forward-looking statements include but are not limited to statements that relate to the expected future business and financial performance, the anticipated benefits of the Transactions, the anticipated impact of the Transactions on the combined business, the expected amount and timing of the synergies from the Transactions and the anticipated Closing Date of the Transactions. These forward-looking statements are identified by words such as “will,” “expect,” “believe,” “anticipate,” “estimate,” “should,” “intend,” “plan,” “potential,” “predict,” “project,” “aim,” and similar words or phrases. These forward-looking statements are based on current expectations and beliefs of management and current market trends and conditions. These forward-looking statements involve risks and uncertainties that are outside Clearwater’s and Enfusion’s control and may cause actual results to differ materially from those contained in forward-looking statements. These risks and uncertainties include, among others, those set forth under “Risk Factors,” as well as risks and uncertainties relating to:

| • |     | the ability of the parties to consummate the Transactions in a timely manner or at all; |

| • |     | the satisfaction (or waiver) of conditions to Closing of the Transactions; |

| • |     | potential delays in consummating the Transactions; |

| • |     | the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the            
 Transactions that could delay the consummation of the Transactions or cause the parties to abandon the Transactions; |

| • |     | the possibility that Enfusion Stockholders may not approve the Merger Agreement Proposal; |

| • |     | the ability of Enfusion or of Clearwater to timely and successfully achieve the anticipated benefits of the 
 Transactions;                                                                                               |

| • |     | the occurrence of any event, change or other circumstance or condition that could give rise to the termination of 
 the Merger Agreement;                                                                                             |